Chris co-founded Broughton in 2006, having worked previously within global blue-chip pharmaceutical companies and Contract Research Organisations within the medicinal product and medical device sectors.
- Over 25 years’ experience in Analytical and Regulatory Science focussing on inhaled and solid dose pharmaceuticals, medical devices, and nicotine products
- Extensive experience with global regulatory agencies, including US Food and Drug Administration (FDA) and UK Medicines and Healthcare products Regulatory Agency (MHRA)
- Oversees the overall direction of the organisation, ensuring that Broughton’s mission is achieved
- Has a passion for developing Broughton’s services and team members to help accelerate life-enhancing products to market
Chris Allen is the Chief Executive Officer at Broughton. Since obtaining a Bachelor of Science degree in Chemistry and a subsequent Post Graduate Certificate in Analytical Science, he has gained over 25 years of analytical and regulatory experience working in global medical device and pharmaceutical companies and leading CROs. Chris started his career working on both Medical Devices and Pharmaceutical products within Smith+Nephew. Subsequently, Chris moved into inhaled medicines, supporting blue-chip pharmaceutical companies’ drug product registration programs within Melbourn Intertek.
Before co-founding Broughton, Chris moved into a leadership role with Sciantec (Cawood), successfully overseeing its entry into the Veterinary Medicines market, supporting global Marketing Authorizations and site inspections.
Chris co-founded Broughton Laboratories in 2006, with Paul Moran, overseeing its first and successful MHRA Good Manufacturing Practice (GMP) inspection within the first three months. With a focus on supporting Marketing Authorizations and Post Marketing activities within the pharmaceutical sector, Broughton played a pivotal role in obtaining the first UK Medicinal License for an electronic cigarette, a project that started in 2010.
Chris took this combined experience of Pharmaceuticals and Nicotine to expand Broughton’s services to support the development and registration of Reduced-Risk Tobacco Products, including Electronic Nicotine Delivery Systems (ENDS). Rapid growth within this area resulted in the expansion to a second site, and a multi-million-pound (GBP) investment into a custom-built facility, leading-edge analytical equipment and expansion of the team and service offerings. Chris has overseen multiple product applications for Medicinal Marketing Authorization Applications (MAA), EU Tobacco Products Directive (TPD), US Premarket Tobacco Product Application (PMTA) and other global markets. Chris has become well established as a recognized subject matter expert in the science and regulation of pharmaceuticals, medical devices and reduced risk nicotine products.
As Chief Executive Officer of Broughton, Chris’ passion lies in developing the Broughton Team and associated services to deliver life-enhancing products to market for their clients.
Martin Lycka, solicitor, is Director of Regulatory Affairs at GVC Holdings. Martin has been an in-house legal and regulatory counsel to global online gambling operators for over 9 years. He also serves as a board member of the EGBA, ESSA, JDigital and SSV. Prior to joining the gambling industry, Martin worked with inter alia Salans Europe LLP and the Ministry of Foreign Affairs of the Czech Republic. He has graduated from the Prague Law Faculty and has obtained a LLM degree at the College of Europe in Bruges as well as a LLB degree at the University Law London.
With a passion for social responsibility and providing clear, commercially aware legal advice, Linda has been working with Better Collective to bring transparency and fairness to the iGaming industry for the last 3 years.
Driving the Group’s global regulatory compliance and responsible marketing strategy, as well as leading GDPR-readiness initiatives and supporting the Group’s intensive M&A activity and IPO preparations means she has insight into a diverse range of challenges in an increasingly complex regulatory landscape.
Patrick is a senior associate in Wiggin’s Betting and Gaming team, specialising in data protection. Patrick has provided GDPR advice to a wide range of clients in the gambling sector – including operators, white labels and B2B providers – as well as providing data protection advice to clients in the film, technology, and media sectors. Patrick’s data protection advice includes compliance, contract drafting and negotiation, and ICO investigations across all aspects of GDPR and electronic direct marketing.
Patrick is a Certified Practitioner of Data Protection, gaining a distinction from PDP.
A long time security and privacy advocate, Mika has applied his trade in everything from logistics and embedded systems all the way to real-time gambling.
At Smarkets he focuses on the cross-section of security, usability and compliance, with an aim at keeping things practical. An engineer at heart, he likes to automate the mundane so people can focus on the subtle. And as the DPO he helps to balance the needs of competing requirements so that both engineering and compliance are satisfied.
He knows that while everyone says they want security, in reality they want convenience. So, Mika has made it his mission to ensure the two wants are not mutually exclusive.
Tom joined Smarkets shortly after its launch in 2010 and has overseen the company’s customer service, finance, legal and compliance functions during crucial growth-phases of the company. Smarkets is one of the world’s leading betting exchange and prediction market platforms, making peer-to-peer trading on events secure, efficient and exciting. Headquartered in London, with offices in Los Angeles and Malta, the company was founded by a team of finance and software engineering professionals and is backed by Passion Capital and Deutsche Telekom. The Smarkets exchange has processed over £10 billion worth of transactions for customers across the company’s licensed and regulated markets.
Ying Cai is a Director of Supply Chain at Ashvattha Therapeutics with 16 years industrial experience, specializing in clinical supply chain. Ying uses that experience to ensure end to end supply chain efficiency and integrity from raw materials to patients.
